Table 5.
Impact ofGC/GEJC/EAC on patient-reported outcomes in patients with negative/unknown HER2, on first-line treatment
| Total | France | Germany | UK | US | Japan | China | |
|---|---|---|---|---|---|---|---|
| EQ-5D-3L utility index | 672 | 161 | 143 | 145 | 99 | 36 | 88 |
| Mean (SD) | 0.701 (0.285) | 0.510 (0.317) | 0.696 (0.290) | 0.726 (0.255) | 0.750 (0.222) | 0.757 (0.153) | 0.940 (0.060) |
| Median (IQR) | 0.779 (0.585–0.928) | 0.510 (0.275–0.798) | 0.788 (0.564–0.887) | 0.744 (0.620–0.848) | 0.781 (0.594–1.000) | 0.714 (0.672–0.804) | 0.946 (0.923–0.973) |
| EQ-VAS | 675 | 167 | 143 | 144 | 98 | 35 | 88 |
| Mean (SD) | 58.1 (19.8) | 52.3 (20.6) | 53.7 (19.1) | 62.5 (17.3) | 59.7 (23.1) | 67.1 (13.4) | 63.3 (16.7) |
| Median (IQR) | 60 (45–75) | 50 (35–70) | 55 (40–70) | 65 (50–77) | 60 (40–80) | 70 (60–76) | 65 (56–75) |
| FACT: Physical well-being | 679 | 166 | 146 | 145 | 99 | 35 | 88 |
| Mean (SD) | 15.4 (6.3) | 14.5 (5.6) | 12.7 (6.4) | 16.9 (5.9) | 16.8 (6.8) | 18.0 (4.7) | 16.5 (6.0) |
| Median (IQR) | 15 (11–20) | 14 (11–19) | 13 (8–17) | 17 (14–21) | 17 (11–23) | 18 (15–21) | 17 (12–21) |
| FACT: Social/family well-being | 678 | 167 | 144 | 145 | 99 | 35 | 88 |
| Mean (SD) | 18.1 (5.5) | 16.6 (5.7) | 18.5 (5.7) | 18.9 (5.1) | 20.4 (5.4) | 15.9 (5.8) | 17.4 (4.5) |
| Median (IQR) | 19 (13–22) | 17 (12–21) | 19 (15–22) | 19 (16–22) | 21 (17–25) | 17 (11–21) | 18 (14–20) |
| FACT: Emotional well-being | 679 | 167 | 146 | 145 | 97 | 36 | 88 |
| Mean (SD) | 11.8 (5.3) | 11.9 (5.2) | 9.8 (5.7) | 12.3 (4.4) | 12.8 (5.6) | 14.3 (4.4) | 12.2 (5.7) |
| Median (IQR) | 12 (8–15) | 12 (9–15) | 10 (5–14) | 12 (10–15) | 13 (8–18) | 15 (10–17) | 11 (8–17) |
| FACT: Functional well-being | 680 | 168 | 146 | 145 | 97 | 36 | 88 |
| Mean (SD) | 11.2 (6.0) | 9.1 (5.6) | 8.3 (5.6) | 12.6 (4.9) | 15.7 (5.8) | 14.4 (4.8) | 11.3 (5.4) |
| Median (IQR) | 11 (7–15) | 9 (5–13) | 8 (3–12) | 12 (9–16) | 16 (13–20) | 14 (10–18) | 12 (8–14) |
| FACT-Ga | 677 | 167 | 145 | 145 | 96 | 36 | 88 |
| Mean (SD) | 40.9 (14.2) | 39.5 (13.3) | 35.5 (14.2) | 44.2 (13.6) | 44.3 (15.0) | 44.6 (10.5) | 42.1 (14.6) |
| Median (IQR) | 41 (31–51) | 40 (32–48) | 35 (26–44) | 45 (36–53) | 43 (32–58) | 44 (37–51) | 40 (30–56) |
| FACT: Trial outcome index | 602 | 134 | 132 | 130 | 87 | 32 | 87 |
| Mean (SD) | 68.0 (23.6) | 63.8 (20.6) | 57.1 (24.1) | 73.8 (22.0) | 77.8 (25.5) | 75.2 (15.7) | 69.8 (22.6) |
| Median (IQR) | 68 (53–84) | 65 (53–76) | 60 (40–73) | 74 (62–88) | 75 (58–101) | 75 (64–83) | 69 (54–86) |
| FACT-G | 296 | 67 | 43 | 70 | 49 | 18 | 49 |
| Mean (SD) | 56.94 (16.8) | 51 (13.3) | 49.9 (15.2) | 61.3 (18.1) | 62.9 (18.2) | 58 (10.0) | 58.6 (17.1) |
| Median (IQR) | 54 (47–67) | 50 (46–57) | 50 (42–59) | 61 (49–74) | 59 (49–79) | 56 (50–66) | 57 (45–69) |
| FACT: Gastric total | 281 | 58 | 41 | 69 | 47 | 18 | 48 |
| Mean (SD) | 100.4 (28.9) | 94.4 (23.6) | 89.0 (28.6) | 106.9 (31.0) | 106.0 (30.4) | 99.8 (17.7) | 102.4 (30.8) |
| Median (IQR) | 97 (82–121) | 93 (82–102) | 94 (67–108) | 103 (88–126) | 99 (84–129) | 101 (84–116) | 98 (79–129) |
| Katz index | 611 | 151 | 138 | 118 | 81 | 35 | 88 |
| Mean (SD) | 5.1 (1.5) | 5.3 (1.2) | 4.1 (1.9) | 5.5 (1.0) | 5.5 (1.2) | 5.8 (0.6) | 5.3 (1.1) |
| Median (IQR) | 6 (5–6) | 6 (5–6) | 4 (3–6) | 6 (5–6) | 6 (6–6) | 6 (6–6) | 6 (5–6) |
| Interference with daily activities | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Mean (SD) | 4.2 (1.5) | 4.6 (1.5) | 4.8 (1.4) | 3.8 (1.4) | 4.0 (1.6) | 3.8 (1.6) | 3.4 (11.3) |
| Median (IQR) | 4 (3–5) | 5 (3–6) | 5 (4–6) | 4 (3–5) | 4 (2–5) | 4 (2–5) | 4 (3–4) |
| Interference with social life | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Mean (SD) | 4.3 (1.5) | 4.6 (1.4) | 4.8 (1.5) | 3.9 (1.4) | 3.8 (1.6) | 3.9 (1.5) | 4.1 (1.6) |
| Median (IQR) | 4 (3–5) | 5 (4–6) | 5 (4–6) | 4 (3–5) | 4 (2–5) | 4 (2–5) | 4 (3–5) |
EAC Esophageal adenocarcinoma, EQ-5D-3L EuroQol 5-Dimension 3-Level questionnaire, EQ-VAS EuroQol-Visual Analogue Scale, FACT Functional Assessment of Cancer Therapy, FACT-G Functional Assessment of Cancer Therapy-General, FACT-Ga Functional Assessment of Cancer Therapy-Gastric Cancer, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation, UK United Kingdom, US United States